Injective (INJ) Down 90% After $4B Hype: Were the Warning Signs Always There?

Injective has stayed far quieter than during its earlier surge, and INJ price has followed the same direction. Momentum that once carried the project toward multibillion valuation has faded into a prolonged correction. One analyst now argues that the decline did not appear suddenly. Signals of weakness may have existed long before the fall became